BusinessTESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer ChemotherapyBy Nasdaq OMXOct 25, 2017, 11:15 PM UTC
BusinessTESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European CommissionBy Nasdaq OMXApr 26, 2017, 12:31 PM UTC
BusinessTESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European CommissionBy Nasdaq OMXApr 26, 2017, 12:31 PM UTC
BusinessTESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines AgencyBy Nasdaq OMXMar 23, 2016, 1:00 PM UTC
BusinessTESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug AdministrationBy Nasdaq OMXMar 14, 2016, 12:05 PM UTC
